ArticleDiscover oncology2025

Assessing the efficacy of darolutamide in metastatic hormone-sensitive prostate cancer based on subgroup meta-analysis and reconstructed individual patient data.

Fuxun Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.